Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.
Identifieur interne : 000528 ( Main/Exploration ); précédent : 000527; suivant : 000529Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.
Auteurs : Anne-Lise Bienvenu [France] ; Aileen M. Marty [États-Unis] ; Malcolm K. Jones [Australie] ; Stephane Picot [France]Source :
- One health (Amsterdam, Netherlands) [ 2352-7714 ] ; 2020.
Abstract
In the absence of a vaccine the medical and scientific community is looking intensely at utilizing a pre or post exposure drug that could decrease viremia. The search for a medication that could reduce risk of serious disease, and ideally of any manifestation of disease from SARS-CoV2, and of asymptomatic shedding of SARS-CoV2 is of urgent interest. Repurposing existing pharmaceuticals is among the approaches to achieve these ends. We performed a systematic review of all interventional studies registered in ClinicalTrials.gov with a focus on one repurposed drug, Hydroxychloroquine (HCQ). The detailed analysis of these studies, some of them already recruiting, provide an overall picture of HCQ use as a COVID-19 prophylaxis around the world. Among the included studies, all but three were randomized and parallel and most of them (74%, 23/31) were double-blinded to quadruple-blinded studies. We found a great diversity in dosing and nearly all the possible scientifically reasonable regimens are under evaluation. This diversity offers benefits as well as challenges. Importantly, the final analysis of these trials should be done through an extensive reading of the results in regard to the clinical design, it will be crucial to carefully read and evaluate the results of each study in regards to the clinical design rather than quickly glancing a 140 characters-based social media message announcing the failure or success of a drug against a disease.
DOI: 10.1016/j.onehlt.2020.100141
PubMed: 32562480
PubMed Central: PMC7235596
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.</title><author><name sortKey="Bienvenu, Anne Lise" sort="Bienvenu, Anne Lise" uniqKey="Bienvenu A" first="Anne-Lise" last="Bienvenu">Anne-Lise Bienvenu</name><affiliation wicri:level="3"><nlm:affiliation>Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Marty, Aileen M" sort="Marty, Aileen M" uniqKey="Marty A" first="Aileen M" last="Marty">Aileen M. Marty</name><affiliation wicri:level="2"><nlm:affiliation>Translational Medicine; HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Translational Medicine; HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami</wicri:cityArea></affiliation></author><author><name sortKey="Jones, Malcolm K" sort="Jones, Malcolm K" uniqKey="Jones M" first="Malcolm K" last="Jones">Malcolm K. Jones</name><affiliation wicri:level="1"><nlm:affiliation>School of Veterinary Science, The University of Queensland, Brisbane, Qld, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Veterinary Science, The University of Queensland, Brisbane, Qld</wicri:regionArea><wicri:noRegion>Qld</wicri:noRegion></affiliation></author><author><name sortKey="Picot, Stephane" sort="Picot, Stephane" uniqKey="Picot S" first="Stephane" last="Picot">Stephane Picot</name><affiliation wicri:level="3"><nlm:affiliation>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32562480</idno><idno type="pmid">32562480</idno><idno type="doi">10.1016/j.onehlt.2020.100141</idno><idno type="pmc">PMC7235596</idno><idno type="wicri:Area/Main/Corpus">000C92</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C92</idno><idno type="wicri:Area/Main/Curation">000C92</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000C92</idno><idno type="wicri:Area/Main/Exploration">000C92</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.</title><author><name sortKey="Bienvenu, Anne Lise" sort="Bienvenu, Anne Lise" uniqKey="Bienvenu A" first="Anne-Lise" last="Bienvenu">Anne-Lise Bienvenu</name><affiliation wicri:level="3"><nlm:affiliation>Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Marty, Aileen M" sort="Marty, Aileen M" uniqKey="Marty A" first="Aileen M" last="Marty">Aileen M. Marty</name><affiliation wicri:level="2"><nlm:affiliation>Translational Medicine; HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Translational Medicine; HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami</wicri:cityArea></affiliation></author><author><name sortKey="Jones, Malcolm K" sort="Jones, Malcolm K" uniqKey="Jones M" first="Malcolm K" last="Jones">Malcolm K. Jones</name><affiliation wicri:level="1"><nlm:affiliation>School of Veterinary Science, The University of Queensland, Brisbane, Qld, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Veterinary Science, The University of Queensland, Brisbane, Qld</wicri:regionArea><wicri:noRegion>Qld</wicri:noRegion></affiliation></author><author><name sortKey="Picot, Stephane" sort="Picot, Stephane" uniqKey="Picot S" first="Stephane" last="Picot">Stephane Picot</name><affiliation wicri:level="3"><nlm:affiliation>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></analytic><series><title level="j">One health (Amsterdam, Netherlands)</title><idno type="ISSN">2352-7714</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the absence of a vaccine the medical and scientific community is looking intensely at utilizing a pre or post exposure drug that could decrease viremia. The search for a medication that could reduce risk of serious disease, and ideally of any manifestation of disease from SARS-CoV2, and of asymptomatic shedding of SARS-CoV2 is of urgent interest. Repurposing existing pharmaceuticals is among the approaches to achieve these ends. We performed a systematic review of all interventional studies registered in ClinicalTrials.gov with a focus on one repurposed drug, Hydroxychloroquine (HCQ). The detailed analysis of these studies, some of them already recruiting, provide an overall picture of HCQ use as a COVID-19 prophylaxis around the world. Among the included studies, all but three were randomized and parallel and most of them (74%, 23/31) were double-blinded to quadruple-blinded studies. We found a great diversity in dosing and nearly all the possible scientifically reasonable regimens are under evaluation. This diversity offers benefits as well as challenges. Importantly, the final analysis of these trials should be done through an extensive reading of the results in regard to the clinical design, it will be crucial to carefully read and evaluate the results of each study in regards to the clinical design rather than quickly glancing a 140 characters-based social media message announcing the failure or success of a drug against a disease.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32562480</PMID><DateRevised><Year>2020</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2352-7714</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>One health (Amsterdam, Netherlands)</Title><ISOAbbreviation>One Health</ISOAbbreviation></Journal><ArticleTitle>Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.</ArticleTitle><Pagination><MedlinePgn>100141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.onehlt.2020.100141</ELocationID><Abstract><AbstractText>In the absence of a vaccine the medical and scientific community is looking intensely at utilizing a pre or post exposure drug that could decrease viremia. The search for a medication that could reduce risk of serious disease, and ideally of any manifestation of disease from SARS-CoV2, and of asymptomatic shedding of SARS-CoV2 is of urgent interest. Repurposing existing pharmaceuticals is among the approaches to achieve these ends. We performed a systematic review of all interventional studies registered in ClinicalTrials.gov with a focus on one repurposed drug, Hydroxychloroquine (HCQ). The detailed analysis of these studies, some of them already recruiting, provide an overall picture of HCQ use as a COVID-19 prophylaxis around the world. Among the included studies, all but three were randomized and parallel and most of them (74%, 23/31) were double-blinded to quadruple-blinded studies. We found a great diversity in dosing and nearly all the possible scientifically reasonable regimens are under evaluation. This diversity offers benefits as well as challenges. Importantly, the final analysis of these trials should be done through an extensive reading of the results in regard to the clinical design, it will be crucial to carefully read and evaluate the results of each study in regards to the clinical design rather than quickly glancing a 140 characters-based social media message announcing the failure or success of a drug against a disease.</AbstractText><CopyrightInformation>© 2020 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bienvenu</LastName><ForeName>Anne-Lise</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marty</LastName><ForeName>Aileen M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Translational Medicine; HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Malcolm K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>School of Veterinary Science, The University of Queensland, Brisbane, Qld, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Picot</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>One Health</MedlineTA><NlmUniqueID>101660501</NlmUniqueID><ISSNLinking>2352-7714</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Post-exposure prophylaxis</Keyword><Keyword MajorTopicYN="N">Pre-exposure prophylaxis</Keyword><Keyword MajorTopicYN="N">SARS-CoV2</Keyword><Keyword MajorTopicYN="N">clinicaltrials.gov</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32562480</ArticleId><ArticleId IdType="doi">10.1016/j.onehlt.2020.100141</ArticleId><ArticleId IdType="pii">S2352-7714(20)30162-2</ArticleId><ArticleId IdType="pii">100141</ArticleId><ArticleId IdType="pmc">PMC7235596</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
<ReferenceList><Reference><Citation>Clin Infect Dis. 2020 Mar 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32211764</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Apr 25;395(10233):1322-1325</Citation><ArticleIdList><ArticleId IdType="pubmed">32247324</ArticleId></ArticleIdList></Reference><Reference><Citation>One Health. 2020 Apr 4;:100131</Citation><ArticleIdList><ArticleId IdType="pubmed">32292817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Floride</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Bienvenu, Anne Lise" sort="Bienvenu, Anne Lise" uniqKey="Bienvenu A" first="Anne-Lise" last="Bienvenu">Anne-Lise Bienvenu</name></region><name sortKey="Bienvenu, Anne Lise" sort="Bienvenu, Anne Lise" uniqKey="Bienvenu A" first="Anne-Lise" last="Bienvenu">Anne-Lise Bienvenu</name><name sortKey="Picot, Stephane" sort="Picot, Stephane" uniqKey="Picot S" first="Stephane" last="Picot">Stephane Picot</name><name sortKey="Picot, Stephane" sort="Picot, Stephane" uniqKey="Picot S" first="Stephane" last="Picot">Stephane Picot</name></country><country name="États-Unis"><region name="Floride"><name sortKey="Marty, Aileen M" sort="Marty, Aileen M" uniqKey="Marty A" first="Aileen M" last="Marty">Aileen M. Marty</name></region></country><country name="Australie"><noRegion><name sortKey="Jones, Malcolm K" sort="Jones, Malcolm K" uniqKey="Jones M" first="Malcolm K" last="Jones">Malcolm K. Jones</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000528 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000528 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32562480
|texte= Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32562480" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |